vimarsana.com

Latest Breaking News On - Ocuphire pharma - Page 1 : vimarsana.com

HC Wainwright Reaffirms Buy Rating for Ocuphire Pharma (NASDAQ:OCUP)

HC Wainwright restated their buy rating on shares of Ocuphire Pharma (NASDAQ:OCUP – Free Report) in a research note released on Monday morning, Benzinga reports. The brokerage currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Ocuphire Pharma’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.29) […]

Ocuphire Pharma (NASDAQ:OCUP) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Ocuphire Pharma (NASDAQ:OCUP – Free Report) in a research report released on Monday morning, Benzinga reports. The firm currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Ocuphire Pharma’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.29) […]

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Ocuphire Pharma (NASDAQ:OCUP) Price Target Lowered to $18 00 at Canaccord Genuity Group

Ocuphire Pharma (NASDAQ:OCUP) Price Target Lowered to $18 00 at Canaccord Genuity Group
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.